Lighthouse Pharma
Lighthouse Pharma is a clinical-stage biopharmaceutical company pursuing precision medicine approaches and developing precision therapeutics for major unmet medical needs.
- Company
- Novato, CA, USUnited States
Lighthouse Pharma is a clinical-stage biopharmaceutical company pursuing precision medicine approaches and developing precision therapeutics for major unmet medical needs.
lighthousepharma.comCrawled Oct 24, 2026
The U.S. Food and Drug Administration cleared Lighthouse Pharmaceuticals’ Investigational New Drug application for LHP588, a gingipain inhibitor for *P. gingivalis*-positive Alzheimer’s disease.
Novato, CA - Nov 17, 2025 - Lighthouse Pharmaceuticals Presents Phase 2 SPRING Trial of LHP588, a Next-Generation Gingipain Inhibitor for the Treatment of P. gingivalis-Positive Alzheimer’s Disease, at CTAD 2025.
Lighthouse Pharmaceuticals relocated its headquarters to the Buck Institute for Research on Aging in Novato, California.
Lighthouse Pharmaceuticals secured a $12 million Series A financing to advance its lead therapy, LHP588 for Alzheimer’s disease, and expand its pipeline.
Lighthouse Pharma is a clinical stage private biopharmaceutical company pioneering precision medicine approaches to major unmet medical needs. Lighthouse’s lead program, LHP588, is in Phase 2 clinical for P. gingivalis-positive Alzheimer's disease.
Lighthouse Pharmaceuticals secures funding from Marin Sonoma Impact Ventures. The company, based at the Buck Institute for Research on Aging, focuses on developing dementia treatments. This venture capital infusion supports its research and development efforts in neurodegenerative disease therapies.
Jul 2026Silicon ValleyNews article
Lighthouse Pharmaceuticals presents Phase 2/3 GAIN trial data showing that **atuzaginst**, a gingipain inhibitor, improves neuropsychiatric symptoms and lowers caregiver distress in Alzheimer’s patients with *P. gingivalis* infection. The findings highlight potential therapeutic effects of targeting gingipains in this patient subgroup. Results were shared at the **AAIC 2026** conference.
Jul 2026PR NewswireNews article
Lighthouse Pharmaceuticals secures **$12 million in Series A funding**, led by investment firm **Double Point Ventures**. The clinical-stage biopharmaceutical company focuses on developing **small-molecule therapies** targeting **neurodegenerative diseases**. This financing supports its pipeline of novel treatments in early-stage clinical trials.
Apr 2026PR NewswireNews article
Lighthouse Pharmaceuticals presents Phase 2 SPRING trial results for **LHP588**, a next-generation gingipain inhibitor targeting *P. gingivalis*-positive Alzheimer’s disease. The trial evaluates the drug’s potential in addressing a specific subset of Alzheimer’s linked to periodontal pathogen *Porphyromonas gingivalis*. Lighthouse specializes in precision medicine for unmet neurological needs.
Nov 2025PR NewswireNews article